Search Results Within Category "Blood Disorders"
A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
Study of the safety of unlicensed cord blood units for stem cell transplant of children and adults.
For the treatment arm of this study you will no receive the total body radiation (TBI) as typically given before transplant. In this study you will have various research procedures such as a Blast sample at the screening part of the study, and MRD testing of your bone marrow and blood at screening and through the course of the study. Participation in the treatment arm (Non-TBI) of the study will last up to 5 years.
You are receiving unlicensed CB products from other CB banks
Study of Angelica gigas dietary supplements (Cogni.Q) and potential effects on human immune cells
This human study will test the impact of dietary supplement vegicaps containing Korean Angelica root extract on 2 types of human immune cells: neutrophils that kill bacteria and other germs and natural killer (NK) cells that kill virus-infected cells and cancers. We had done an earlier study with Korean Angelica supplement and discovered even a single dose of it increased blood neutrophils and NK cells within 24 h. In the new study, Korean Angelica capsules (Cogni.Q) will be compared head-to-head with dummy (placebo) capsules. This is to make sure the immune boosting actions are really from the Korean Angelica supplement.Approximately 40 men will take part in this research study at Hershey Medical Center.
Subjects weighing between 110 to 240 pounds; their body mass index (BMI) should be in the range of 19=< BMI >=30
Subjects having normal hepatic, renal function as assessed by history, physical and clinical chemistry analysis (CMP eGFR).
Subjects with normal blood pressure (systolic below 120 mm Hg and diastolic below 80 mm Hg)
Subjects taking any kind of prescription medications regularly or within 10 days of the study will be excluded.
Subjects taking dietary or herbal supplements that contain AGN (e.g. Cogni.Q, Decursinol-50, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) within 10 days of the study.
Non-English-speaking subjects
ATHN 10: Leveraging the ATHNdataset to Document the State of RareCoagulation Disorders in the United States
This is a multi-center project in which the American Thrombosis & Hemostasis Network (ATHN) will offer free genotyping to individuals with Rare Coagulation Disorders (RCD).
One tube of blood will be collected during a routine clinic visit.
Must currently receive or have received care at and ATHN affiliated HTC
Subject must have opted into the ATHNdataset
Open-label safety study in adults and adolescents with haemophilia A with and without FVIII inhibitors switching directly from emicizumab prophylaxis to NNC0365-3769 (Mim8) prophylaxis
A research study looking at how safe it is to switch from emicizumab (Hemlibra) to Mim8 in people with haemophilia A.
The study will last for about 6-12 months. Subjects will have between 6 and 27 Mim8 injections depending on dosing frequency. There will be 9 clinic visits. Blood will be drawn at all 9 of the visits.
$75 per visit to cover travel expenses
Treated with emicizumab QW, Q2W, or Q4W according to the label for at least 8 weeks prior to screening.
Age 12 years or above at the time of signing the informed consent.
Patients for whom the decision to discontinue emicizumab treatment has been made.
Willingness and ability to comply with scheduled visits and study procedures, including the completion of an electronic diary and patient-reported outcomes (PRO) questionnaires.
Previous or current thromboembolic disease or events or risk of thromboembolic disease, as evaluated by investigator or risk of thromboembolic disease, as evaluated by investigator.
Receipt of FVIII gene therapy at any time.
Ongoing or planned immune tolerance induction therapy.
Minor or major surgery planned to take place after screening and during the 26-week treatment period.
A Global, Open-Label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
This is an open-label drug study of SerpinPC (a subcutaneously administered drug) for patients with severe hemophilia A or moderately severe to severe Hemophilia B. The study consists of 3 parts after an observation phase of 12-24 weeks: 24 week justification phase, 24 week confirmatory phase & 24 week extension phase.
This is a subcutaneous drug treatment clinical trial with an observation period of up to 24 weeks, pre-dosing/dosing period of 8 visits on site or phone calls & an extension period of 6 visits.
$75.00 travel reimbursement per visit
Subjects include prophylactic dosing or on-demand dosing for factor replacement
Adequate laboratory functions
Previous deep vein thrombosis, pulmonary embolism, MI or stroke.
Uncontrolled hypertension, active cancer (except basal cell)
Weight > 150kg (330 lbs.) or BMI > 40kg/m2
A Phase 3, single-arm, open-label, multicenter study of thesafety and efficacy of dirloctocogene samoparvovec(SPK-8011, adeno-associated viral vector with B-domaindeleted human factor VIII gene) in adults with severe ormoderately severe hemophilia A (KEYSTONESM 1)
This is a Phase 3 study of single-dose SPK-8011 AAV gene therapy in combination with immunomodulation. Patients will receive a one-time dose of SPK 8011, three weeks of methylprednisolone & then will be followed for safety & efficacy per study schedule.
1) Screening period of < 8wks.-1 visit2) Lead-in for >24 wks.-1 visit3) Pre-dose day -24-1 visit4) Dosing-Day 1 & Day 2-2 visits5) Primary study (15 mos.)-37 visits6) Long term follow-up approx. 9 yrs.-20 visitsSome visits may be done via home health when a physical isn't required.
$75.00 travel reimbursement per visit
>150 documented exposure days to a FVIII protein product
No evidence of cirrhosis or advanced liver disease
Negative test for inhibitor against FVIII during screening
No documented FVIII inhibitor in 5 yrs. prior to screening
Currently undergoing antiviral therapy
Have an inherited bleeding or acquired disorder other than hemophilia A
Prior treatment with a vector or gene transfer agent
Major surgical procedure planned in a 15 month period following SPK 8011 infusion
Understanding the Relationship Between Discrimination and Sickle Cell Pain
This is a survey and interview study recruiting patients with sickle cell disease (SCD). Participants will answer questionnaires and complete a remote interview about health care experiences, pain, and discrimination. Natural language processing of interview transcripts will be used to quantify linguistic features indicative of subjective associations between individual experiences of racial discrimination and sickle cell pain.
Participants will be asked to fill out questionnaires and answer questions during an interview.
$50
18 years or older
Does not have a confirmed diagnosis of Sickle Cell Disease
Unable or unwilling to participate in the interview or to be recorded
Not Fluent in the English langauge